Roche, Chugai Pharma to transfer Bonviva business in Japan to Taisho Pharma

Chugai and Taisho concluded an agreement in 2006 to co-develop and co-market Bonviva in Japan. After conducting clinical studies in Japan, the two companies have been jointly marketing Bonviva since the launch of the injection in 2013. In consideration of the maturity of the product lifecycle, Chugai, Taisho, and Roche revisited the marketing of Bonviva in Japan and concluded that Taisho should solely market Bonviva after transferring assets related to Bonviva that are owned by Roche and Chugai, including the marketing authorization and intellectual property rights (patents and trademarks, etc.), to Taisho.

Read also: Roche gets USFDA nod for VENTANA FOLR1 RxDx Assay to detect ovarian cancer patients eligible for ELAHERE

Following the signing of the asset purchase agreement, Taisho and Chugai will proceed with the necessary administrative and legal procedures for the completion of the transaction. The transfer of the marketing authorization is scheduled to take place on April 3, 2023. Taisho will be solely responsible for the marketing of and information provision activities for Bonviva in Japan thereafter.

Read also: Chugai Pharma Herceptin gets Japanese nod for additional indication of salivary gland cancer

Roche is a Swiss multinational healthcare company headquartered in Basel, Switzerland.